Ensysce Biosciences, Inc. (ENSC) Latest Company News

Sep 15, 2026, 13:15 UTC
Ensysce Biosciences hosted a symposium on its CRPS program at PainWeek 2026, attended by more than 320 pain management professionals.
Source:
- accessnewswire.com
Sep 14, 2026, 12:00 UTC
Richard Langford, Chief Medical Officer of Cy Biopharma, was selected to present at the U.S. Food and Drug Administration's public hearing on the potential future therapeutic use of psychedelic drugs, held on September 14, 2026 at the FDA's White Oak Campus in Silver Spring, Maryland.
Source:
- accessnewswire.com
Aug 31, 2026, 12:30 UTC
Ensysce Biosciences announced completion of enrollment in the final stage of its PF614-MPAR-102 clinical study evaluating its MPAR overdose-protection technology.
Source:
- accessnewswire.com
Aug 18, 2026, 17:31 UTC
Ensysce Biosciences, Inc. announced a private placement financing.
Source:
- seekingalpha.com
Aug 18, 2026, 17:31 UTC
Ensysce Biosciences, Inc. announced the acquisition of Cy Biopharma.
Source:
- seekingalpha.com
Aug 13, 2026, 20:15 UTC
Ensysce Biosciences completed its acquisition of Cy Biopharma, adding the CY200 program for complex regional pain syndrome, and secured up to $77 million in new funding.
Source:
- accessnewswire.com
Aug 13, 2026, 00:00 UTC
Ensysce Biosciences reported Q2 2026 revenue of $1.16 million, a net loss of $2.57 million, and diluted EPS of -$0.20, with cash and cash equivalents of $0.68 million at quarter end.
Aug 6, 2026, 12:00 UTC
Ensysce Biosciences entered into a definitive agreement for the sale of Series C non-voting convertible preferred stock in a private placement financing expected to raise approximately $21.5 million at initial close, on August 6, 2026.
Source:
- accessnewswire.com
Aug 6, 2026, 12:00 UTC
Ensysce Biosciences completed the acquisition of Cy Biopharma, a privately held clinical-stage biotechnology company developing neuroplastogenic therapies for complex pain, on August 6, 2026.
Source:
- accessnewswire.com
Jul 14, 2026, 12:00 UTC
Ensysce Biosciences received a $5.3 million installment from the National Institutes on Drug Abuse (NIDA) as part of a multi-year $15 million federal grant to support development of its MPAR overdose-protection technology and lead agent PF614-MPAR.
Source:
- accessnewswire.com
Jun 26, 2026, 12:00 UTC
Ensysce Biosciences enrolled the first patient in the final phase of its PF614-MPAR-102 clinical study, evaluating its MPAR overdose-protection technology.
Source:
- accessnewswire.com

ENSC

Ensysce Biosciences hosted a symposium on its CRPS program at PainWeek 2026, attended by more than 320 pain management professionals.

Richard Langford, Chief Medical Officer of Cy Biopharma, was selected to present at the U.S. Food and Drug Administration's public hearing on the potential future therapeutic use of psychedelic drugs, held on September 14, 2026 at the FDA's White Oak Campus in Silver Spring, Maryland.

Ensysce Biosciences announced completion of enrollment in the final stage of its PF614-MPAR-102 clinical study evaluating its MPAR overdose-protection technology.

Ensysce Biosciences, Inc. announced a private placement financing.

Ensysce Biosciences, Inc. announced the acquisition of Cy Biopharma.

Ensysce Biosciences completed its acquisition of Cy Biopharma, adding the CY200 program for complex regional pain syndrome, and secured up to $77 million in new funding.

Ensysce Biosciences reported Q2 2026 revenue of $1.16 million, a net loss of $2.57 million, and diluted EPS of -$0.20, with cash and cash equivalents of $0.68 million at quarter end.

Ensysce Biosciences entered into a definitive agreement for the sale of Series C non-voting convertible preferred stock in a private placement financing expected to raise approximately $21.5 million at initial close, on August 6, 2026.

Ensysce Biosciences completed the acquisition of Cy Biopharma, a privately held clinical-stage biotechnology company developing neuroplastogenic therapies for complex pain, on August 6, 2026.

Ensysce Biosciences received a $5.3 million installment from the National Institutes on Drug Abuse (NIDA) as part of a multi-year $15 million federal grant to support development of its MPAR overdose-protection technology and lead agent PF614-MPAR.

Ensysce Biosciences enrolled the first patient in the final phase of its PF614-MPAR-102 clinical study, evaluating its MPAR overdose-protection technology.